Get the latest tech news
Third patient dies from acute liver failure caused by a Sarepta gene therapy
A third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy.Like two dea...
By Steve Usdin, Washington Editor A third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy. Like two deaths associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the most recent death was caused by acute liver toxicity, Sarepta Therapeutics Inc.(NASDAQ:SRPT) spokesperson Tracy Sorrentino told BioCentury.
Or read this on Hacker News
